In early estrogen receptor (ER)+human epidermal growth factor receptor-2 (HER2)- breast cancer, the use of a 21-gene expression assay to guide decision making for adjuvant treatments is widely accepted as part of the standard of care (1–4). The gene discussed is ESR1; the disease is breast cancer.